Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 5/20 | 0.33 |
| ▸ | KIT | P10721 | 3/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 4/20 | 0.31 |
| ▸ | DRD3 | P35462 | 4/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | MTOR | P42345 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20934880 | 0.83 | APP (0.39) | PTH1RMAP4K4MAPT | |
| SCHEMBL20934859 | 0.82 | MAPT (0.37) | PTH1RMAPT | |
| SCHEMBL31247376 | 0.78 | HDAC1 (0.36) | KITHDAC1HDAC6DRD2DRD3 | |
| SCHEMBL20934767 | 0.76 | FPR2 (0.37) | DRD2DRD3MAPTDRD4 | |
| SCHEMBL5694416 | 0.76 | MAOA (0.43) | MAP4K4HDAC1HDAC6PIK3CAMTOR | |
| SCHEMBL24375405 | 0.75 | BTK (0.34) | KITDRD2DRD3DRD4 | |
| SCHEMBL20929322 | 0.73 | MAPT (0.42) | KITHDAC1HDAC6PIK3CAMTOR | |
| SCHEMBL18779716 | 0.71 | KCNH3 (0.40) | HDAC1HDAC6GABRPGABRDGABRA1 | |
| SCHEMBL19981909 | 0.70 | ADRA2A (0.40) | PIK3CAMTORMAPT | |
| SCHEMBL24618881 | 0.70 | KIT (0.50) | KITMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2023-02-09 | — | — | US | disclosed |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-10-25 | — | — | US | disclosed |
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125785-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A4, CYP4B1, CYP3A5 | PTH1R 3546/4885KIT 2049/4885MAP4K4 1479/4885 |
| US-11478474-B2 | 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor | BTK, SYK, LCK | PTH1R 2044/4885KIT 615/4885MAP4K4 337/4885 |
| US-20230043030-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | PTH1R 1778/4885KIT 627/4885MAP4K4 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.